Background: Optimal antibiotic prophylaxis duration in head and neck cleancontaminated free-flap cases is unknown.
prophylaxis in a variety of clean-contaminated head and neck procedures and suggested that (1) antibiotic prophylaxis reduced the risk of surgical site infections, [3] [4] [5] [6] [7] (2) prolonged prophylactic antibiotics do not generally result in reduced surgical site infections, [8] [9] [10] [11] [12] [13] and (3) b-lactam antibiotics are appropriate first-line agents, with clindamycin reserved for patients with b-lactam allergies. [3] [4] [5] 7, [14] [15] [16] [17] As a result of these studies, the Center for Disease Control (CDC) guidelines recommend that patients undergoing clean-contaminated head and neck surgery receive no further antibiotics after the incision is closed. 18 In 2003, the Surgical Care Improvement Project (SCIP) was introduced in a multiorganizational effort to improve surgical outcomes and reduce the incidence of surgical site infection. The 3 main surgical site infection-related SCIP objectives include: (1) initiation of prophylactic antibiotics within 1 hour of surgical incision (within 2 hours for vancomycin or fluoroquinolones); (2) appropriate use of prophylactic antibiotics; and (3) cessation of prophylactic antibiotics within 24 hours of the surgical end time. 19 These guidelines, along with those by the American Society of Health-Systems Pharmacists (ASHP), recommend use of perioperative antibiotics for head and neck surgical procedures; however, maintaining antibiotics beyond 24 hours is not recommended. 19 Recommended agents for clean-contaminated cases include cefazolin or cefuroxime plus metronidazole, ampicillin-sulbactam, or, in cases of penicillin allergy, single-agent clindamycin. 19 The use of microvascular free tissue transfer has allowed complex head and neck defects to be reconstructed reliably with an overall flap survival rate of 95% or greater. [20] [21] [22] [23] However, flap reconstruction is a significant independent risk factor for recipient surgical site infection in cleancontaminated head and neck operations. 12, [24] [25] [26] [27] Although surgical site infection is detrimental in any head and neck case, recipient surgical site infection can be even more devastating in cases of free flap reconstruction due to the risks of flap failure, resultant prolonged hospitalization, orocutaneous or pharyngocutaneous fistula, and need for additional surgery. 28, 29 Despite recommendations from the CDC, 18 SCIP, 19 and ASHP 19 recommending against administration of prophylactic antibiotic therapy beyond 24 hours, postoperative antibiotics are often maintained in patients at the clinician's discretion, 30 with many clinicians administering >24
hours of prophylactic antibiotics in cases of flap reconstruction. There is likely little agreement on antibiotic prophylaxis in this population due to the lack of explicit recommendations given for head and neck clean-contaminated free flap cases. Thus, the purpose of our study was to: (1) systematically review the literature regarding use of prophylactic antibiotics in patients undergoing microvascular free-flap reconstruction for clean-contaminated head and neck defects; and (2) perform a meta-analysis of eligible studies to compare short duration versus prolonged prophylactic antibiotics as a means of reducing postoperative surgical site infection. We secondarily performed an exploratory post hoc analysis to determine if antibiotic type or duration plays a role in recipient surgical site infection or donor site surgical infection risk, risk of dehiscence/fistula, distant infections (pneumonia or urinary tract infection [UTI]), methicillin-resistant staphylococcus aureus, and Clostridium difficile infections.
| MA TERI A LS AND M ETH ODS
This study was exempt from review by our institutional review board as this was a systematic review and metaanalysis of publically available articles. Throughout the study, the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement was followed.
| Search strategy
Two authors (Y.H. and P.T.) independently reviewed the literature for studies presenting data on antibiotic prophylaxis in head and neck clean-contaminated free-flap cases. The search was initiated on March 9, 2016, with an update through December 1, 2016, in PubMed/MEDLINE, Scopus, The Cochrane Library, and Web of Science from the inception of each database. The detailed search strategy performed is shown in Supporting Information Table  S1 . Finally, we examined the reference lists of all relevant publications to locate additional studies meeting our eligibility criteria.
| Study selection and data extraction
Inclusion and exclusion criteria are demonstrated in Table 1 . The search method and results of the search are shown in Figure 1 . The authors of all articles meeting these criteria were contacted 3 times in an effort to obtain their raw data. If there was no response, the raw data were not available, or the information in the article was insufficient for analysis, the study was excluded. If the data reported in the article were sufficient for analysis, the study was still included, regardless of author response. The Cochrane Cystic Fibrosis and Genetic Disorders November 2004 study selection, quality assessment, and data extraction form were used to assess study quality and extract the pertinent data from each article that met inclusion criteria. Ultimately, 5 studies were appropriate for inclusion. [31] [32] [33] [34] [35] From the identified studies, we extracted relevant clinical information regarding the number of patients receiving short-term (24 hours) prophylactic antibiotics, the number of patients receiving long-term (>24 hours) prophylactic antibiotics, and the risk of recipient surgical site infection. For studies reporting secondary endpoints of interest in the obtained raw data, we also extracted information of antibiotic type, rates of distant infections (UTIs or pneumonia), rates of methicillin-resistant staphylococcus aureus (MRSA) infections, and rates of Clostridium difficile (C. diff) gastrointestinal infections in the groups of patients receiving 24 hours and >24 hours of prophylactic antibiotics.
| Statistics
The null hypothesis for this study is that prolonged (>24 hours) prophylactic antibiotic administration has no effect on the risk of recipient surgical site infection in head and neck clean-contaminated free-flap cases. A meta-analysis was used to examine this hypothesis based on 5 published studies [31] [32] [33] [34] [35] clinical signs not meeting criteria for a recipient surgical site infection). Given the results of the primary meta-analysis, which differed from our study's null hypothesis, we further sought to correct for antibiotic type and determine if there continued to be an effect on antibiotic prophylaxis duration on recipient surgical site infections. The antibiotic type was chosen as a variable because it has been previously shown in multiple studies, including that of the largest study in our meta-analysis, 33 to affect the risk of recipient surgical site infection. We also further wished to determine in this post hoc analysis whether antibiotic duration can affect further postsurgical outcomes, including risk of donor site surgical infection, distant infections (UTI or pneumonia), dehiscence/fistula, C. diff, and MRSA. Post hoc analyses were performed on a subset of 3 studies 32, 33, 35 in which individual-level data were available from the original authors to determine the impact of antibiotic type on the risk of recipient surgical site infection in the short (24 hours) versus long duration (>24 hours) prophylactic antibiotic groups. Mixed effect logistic regression model with a study random effect (to account for correlation within study) was used to assess the association between recipient surgical site infection and antibiotic type, duration (24 hours vs >24 hours) as adjusting covariate. Effect modification of antibiotic type was also examined by adding the interaction term of antibiotic type and duration. Similarly, post hoc analyses of secondary outcomes included donor site surgical infections, distant infections, and dehiscence/fistula. Statistical analyses were performed using SAS version 9.4 (Cary, NC) and the R software package "metaphor" (Vienna, Austria 2013).
| R ES ULT S

| Results of systematic review
The sequence of review and exclusion of studies is summarized in the flowchart shown in Figure 1 . The initial search yielded 3127 articles. The subsequent review of reference lists of these yielded an additional 628 articles for a total pool of 3755 articles reviewed. 31 for a total of 5 studies meeting inclusion criteria with sufficient available data to proceed with a meta-analysis (Table 2) . [31] [32] [33] [34] [35] Four of the studies [32] [33] [34] [35] required the raw data for inclusion in the metaanalysis, whereas 1 study 31 did not have available raw data but had sufficient data within the article for inclusion. Three of those 4 studies had information available for a post hoc analysis with individual-level data available, which included additional information about antibiotic type and risk of donor site surgical infections, distant infections, dehiscence/fistula, C. diff, and MRSA.
| Primary analysis of short-term versus long-term antibiotics on risk of recipient surgical site infection
The overall percentage of recipient surgical site infections ranged from 6.6% to 22.1%. The results of the random and fixed effects model of the meta-analysis performed on the 5 included studies regarding the 4 utilized definitions of shortterm and long-term antibiotic prophylaxis is demonstrated in Table 3 . The risk of recipient surgical site infection was significantly higher in the short-term group (24 hours) compared with the long-term group for antibiotic prophylaxis use (>24 hours) in the fixed effect model (RR 1.56; 95% CI 1.13-2.14), with minimal heterogeneity in the results (chisquare 1.62; P 5 .8059; Table 4 ). The sensitivity analysis of recipient surgical site infection risk based on the random effect model showed a similar result (RR 1.60; 95% CI 1.17-2.20; see Table 3 ). Other analyses that examined antibiotic prophylaxis use durations yielded a similar conclusion that the risk of recipient surgical site infection is lower with longer duration of antibiotic prophylaxis use, even when examining short-term prophylaxis as 48 hours or when excluding patients who had >7 days of antibiotic prophylaxis ( Figure 2 , Table 3 ). There was similarly no significant evidence of heterogeneity across studies (Table 4 ).
| Post hoc analysis evaluating effect of antibiotic type on recipient surgical site infection
Given the findings of a statistically significant reduction in recipient surgical site infections among those receiving prolonged antibiotic therapy, which differed from our null hypothesis, we performed a post hoc multivariate analysis to determine whether antibiotic type was associated with recipient surgical site infections, donor site surgical infections, distant infections, dehiscence/fistula, MRSA, and C. diff infections. Individuallevel data were required for this analysis and was available and obtained from the authors of 3 studies. 32, 33, 35 A total of 697 patients from these were included. Antibiotics were characterized into 3 groups: (1) antibiotic group within the "others" category contained a sufficient number of patients to be analyzed separately and, thus, were grouped together. The overall percentage of recipient surgical site infection in this population was 16.9%. As shown in Table 5 , the mixed effect logistic regression model demonstrated no statistically significant difference in recipient surgical site infection when comparing 24 hours to >24 hours of prophylactic antibiotics after accounting for antibiotic type (RR 1.09; 95% CI 0.78-1.55; P 5 .6082). When compared to ampicillin-sulbactam, patients who received clindamycin prophylaxis had an increased likelihood of recipient surgical site infection (RR 2.85; 95% CI 1.95-4.17; P < .001).
| Post hoc analysis of secondary outcomes
As seen in Table 5 , the overall percentage of donor site surgical infections in this population of 697 patients was 10.6%, dehiscence/fistula was 17.9%, distant infection (pneumonia or UTI) was 17.9%, MRSA was 6.2%, and C. diff was 1.6%. Due to the low prevalence of C. diff, further analysis of this outcome based on antibiotic type The inherent risk factors of this patient population and this surgery can also contribute to an increased risk of surgical site infections. 39 These risk factors include a higher patient American Society of Anesthesiologist score, increased duration of surgery, increased tendency for intraoperative blood loss, and increased preoperative T classification, which can increase surgical invasiveness and postoperative soft tissue dead space. 39 Most clinicians agree that antibiotic prophylaxis should be administered perioperatively in head and neck clean-contaminated free-flap cases, with studies demonstrating a significantly increased risk of surgical site infection when prophylactic antibiotics are not administered. 40 However, there is a lack of clinician agreement on the optimal duration of antibiotic prophylaxis in these cases. Although our initial meta-analysis revealed a Abbreviations: CI, confidence interval; MRSA, methicillin-resistant Staphylococcus aureus; PNA, pneumonia; RR, relative risk; UTI, urinary tract infection. Ampicillin-sulbactam was set at the reference point (RR of 1) with clindamycin and "others" being compared to ampicillin-sulbactam (eg, clindamycin carries a 2.85 times increased risk of recipient surgical site infection compared to ampicillin-sulbactam).
difference in risk of recipient surgical site infection based upon duration of antibiotic usage, this difference was no longer significant when the type of antibiotic utilized was evaluated in multivariate analysis performed on raw data from the 3 largest studies. In this multivariate analysis, there was no difference in the risk of recipient surgical site infections, donor site surgical infections, dehiscence/fistula, distant infections (pneumonia or UTIs), or MRSA infections when antibiotics are administered for >24 hours compared with 24 hours. Although a strong conclusion regarding the optimal duration of antibiotic prophylaxis in head and neck clean-contaminated free-flap cases remains elusive, the results of this analysis suggest that 24 hours of appropriately chosen antibiotic prophylaxis is likely sufficient in head and neck clean-contaminated free-flap cases, especially when considering the risk of prolonged antibiotic administration. Perioperative antibiotic regimens aim to provide adequate coverage of common oral flora, including Streptococci, Staphylococci, Bacteriodes, Peptostreptococcus, Prevotella, and Fusobacterium species and Enterobacteriaceae. 19, 41 The ASHP guidelines advocate the use of prophylactic cefazolin with metronidazole, cefuroxime with metronidazole, or ampicillin-sulbactam for oncologic clean-contaminated head and neck surgery. The guidelines also suggest the use of clindamycin in patients with a b-lactam allergy. 19 At present, according to ASHP guidelines, any 1 of these regimens are considered adequate perioperative therapy in the prevention of surgical site infection in clean-contaminated head and neck cases. In our analysis, clindamycin carried a 2.85 times increased risk of recipient surgical site infection and 2.51 times increased risk of dehiscence/fistula when compared to ampicillin-sulbactam. Interestingly, a protective effect on donor site surgical infection was seen with clindamycin administration, which we could not fully explain. Although clindamycin should have adequate gram-positive coverage at the donor site, we would not expect this coverage to be better than ampicillin-sulbactam and, thus, the reason behind this statistical result is unclear. However, given the increased risk of recipient surgical site infection with clindamycin prophylaxis, the authors of this study would suggest a modification to the ASHP guidelines such that additional gram-negative coverage is administered in head and neck clean-contaminated free-flap cases in patients with b-lactam allergy. Previous studies have similarly suggested an increased risk of recipient surgical site infections with prophylactic clindamycin compared to ampicillin-sulbactam in cleancontaminated head and neck cases, 15, 29, 33, 35, [42] [43] [44] [45] although this association was not demonstrated in all studies. 16 Surgical site infections in head and neck clean-contaminated cases are often polymicrobial 46 and can include gram-negative aerobic bacteria (eg, Escherichia coli, Klebsiella pneumoniae, or Pseudomonas aeruginosa) for which clindamycin does not offer coverage. 47 Furthermore, elevated or increasing clindamycin resistance of methicillin-resistant and methicillin sensitive Staphylococcus aureus (40%-45%) 48 and Bacteroides (34%-47%) 49 has been reported. Last, patients with head and neck squamous cell carcinoma of the upper aerodigestive tract, which comprise a large subset of the population requiring microvascular reconstruction, harbor increased levels of intraoral gram-negative bacteria, 50 suggesting that they may require broader prophylaxis, for which clindamycin is not sufficient. Although ampicillin-sulbactam is the most common choice of antibiotic for prophylaxis in head and neck cleancontaminated free-flap cases, clindamycin alone continues to be used among clinicians. Clindamycin is typically used by clinicians in cases of penicillin allergy. However, a true penicillin allergy is present in only 10% of the population who report an allergy. 51 Thus, in 90% of patients reporting an allergy, a b-lactam antibiotic can likely be safely administered. Allergy confirmation or desensitization in patients with a possible b-lactam allergy can be performed but may be unrealistic depending on the circumstances. At the very least, given the increased risk of recipient surgical site infection with clindamycin prophylaxis demonstrated in this meta-analysis and several other studies, administration of an additional antibiotic with increased gram-negative coverage should be considered in patients with penicillin allergies. Based on the available literature, including the data available from this systematic review and meta-analysis, we would suggest that 24 hours of appropriately chosen antibiotic prophylaxis is likely sufficient in head and neck cleancontaminated free-flap cases. However, the finding of the meta-analysis on 5 includable studies that >24 hours of antibiotic administration offered a protective effect against recipient surgical site infection is difficult to completely ignore. Future studies into the duration of antibiotic prophylaxis in these higher risk cases may ultimately demonstrate a protective effect of prolonged antibiotic administration. However, at this point, all available data would suggest that the patient population receiving free flap reconstruction of head and neck clean-contaminated defects should receive similar duration antibiotic prophylaxis (24 hours) as other cleancontaminated head and neck cases, despite the increased risk factors for infection seen in this patient population. This study was able to demonstrate with greater certainty that clindamycin as single drug therapy is associated with an increased risk of recipient surgical site infection, dehiscence/ fistula, MRSA, and distant infections when compared to ampicillin-sulbactam. Thus, the authors of this study would suggest that clindamycin antibiotic prophylaxis is inadequate in head and neck clean-contaminated free-flap cases.
As with many systematic reviews and meta-analyses, we are limited by the available data of the current literature and unable to testify to the quality of the data obtained. Our data rests on individual case-control or retrospective case series with small sample sizes. In addition, inherent to all systematic reviews is the limitation that includable studies could be missed, despite the authors' best efforts to be thorough and comprehensive. The evaluation of the risk of surgical site infections with the use of prophylactic antibiotics is best addressed with prospective randomized clinical trials.
In addition, many studies in the current literature do not use a uniform definition of surgical site infection. The CDC defines surgical site infection as an infection occurring within 30 days of surgery and including at least 1 of the following: (1) purulent drainage from the incision; (2) an incision that spontaneously dehisces or is deliberately opened by a surgeon and is culture-positive or not cultured and the patient has clinical signs of infection (fever and/or localized pain or tenderness); (3) an abscess or other evidence of infection involving the deep tissue that is detected on gross, anatomic, or histopathologic examination or imaging; or (4) diagnosis of surgical site infection made by the surgeon. 52 All but one study in our meta-analysis used this definition for surgical site infection. 31 Furthermore, we must assume that antibiotics were given on time and dosed appropriately to achieve therapeutic steady-state concentrations. 34 Additionally, this type of analysis precluded our ability to adjust for preoperative risk factors that can affect the rates of surgical site infections, such as body mass index, diabetes mellitus, tracheotomy, length of surgery, or history of radiation. This lack of uniformity makes it difficult to standardize the risk of surgical site infections in head and neck cleancontaminated cases, especially when subjectivity and variability may exist with respect to the surgeon's ability to definitely identify and document a surgical site infection.
| C ONCL US I ON
Although a strong conclusion regarding the optimal duration of antibiotic prophylaxis in head and neck cleancontaminated free-flap cases remains elusive, the results of this analysis suggest that 24 hours of appropriately chosen antibiotic prophylaxis is likely sufficient in head and neck clean-contaminated free-flap cases, especially when considering the risk of prolonged antibiotic administration. In this analysis, clindamycin prophylaxis was noted to be inadequate when compared to ampicillin-sulbactam in head and neck clean-contaminated free-flap cases. Prospective randomized clinical trials that are adequately powered to examine the duration and types of antibiotic prophylaxis are needed to better clarify the question of the optimal duration of antibiotic prophylaxis in clean-contaminated head and neck microvascular cases.
